PASADENA, Calif., May 22, 2019 /PRNewswire/ -- Dr.
Neil Singla, Chief Executive Officer
of Lotus Clinical Research, Chaired the fourth annual American
Pain Society Conference on Analgesic Trials (APS-CAT), which
showcased experts in the analgesic clinical trial space who
discussed accelerating the development of non-opioid pain medicines
via improved clinical trial design and conduct. According to the
U.S. Department of Health and Human Services
(https://www.hhs.gov/opioids/about-the-epidemic/index.html), 2.1
million people in the United
States experienced an opioid use disorder in 2017, and of
those, over 43,000 died from opioid overdoses. APS-CAT provided a
forum for industry experts to collaborate with academicians,
scientists, researchers and regulatory experts to share new ideas
and best practices in the design and conduct of clinical pain
trials, via speaker presentations and open question and answer
sessions with the audience.
Neil Singla, MD presented on
"Acute vs. Chronic Pain: Experimental Models, Regulatory Pathways
and Market Opportunities." The speaker panel also included
Nathaniel Katz, CEO, Analgesic
Solutions; Robert Dworkin, Ph.D.,
Professor of Anesthesiology and Perioperative Medicine, Neurology,
and Psychiatry, University of Rochester
Director, ACTTION public-private partnership with the FDA;
William Schmidt,
PhD, President, NorthStar Consulting; Michael Oshinsky, MD, Program Director,
Pain and Migraine, National Institute of Neurological Disorders and
Stroke, National Institutes of Health; and Lee Simon, MD, Principal, SDG, LLC
& Former Director, FDA Division of Analgesic,
Anti-inflammatory and Ophthalmologic Drug Products.
Industry leaders Barry Quart, Pharm. D., CEO, Heron
Therapeutics; Scott Kelley,
MD, CMO, Flexion Therapeutics and James Campbell, MD, President and CSO,
Centrexion Therapeutics, shared their personal experience and
perspectives on scientific, regulatory and economic concerns for
rapid development of non-opioid analgesics. The open forum format
of the conference allowed audience members to ask questions about
lessons learned on the pathway to FDA approval, in a joint effort
to help support the rapid development of non-opioid pain medicines
to help combat the opioid epidemic.
"This was my first APS-CAT meeting and it was gratifying to
interact with a diverse audience that included government,
academic, and pharma/biotech pain product development
constituents," said William Moore,
CEO of Vizuri Health Sciences. "The meeting topics were current and
informative, and I was able to personally meet with experts who can
help Vizuri advance its innovative topical pain product,
CGS-200."
The American Pain Society hosted APS-CAT as part of its 2019
Scientific Meeting, where presenters shared emerging advancements
in pain research and clinical practice with the central theme
"Combating the Opioid Epidemic through Innovations in the Treatment
of Pain". APS-CAT continues to receive overwhelmingly positive
feedback with respected thought leaders in analgesic clinical
research working to improve clinical pain trials through discussion
on topics including experimental methods to increase analgesic
trial assay sensitivity and the pros/cons of common clinical pain
models.
About Lotus Clinical Research: Lotus Clinical
Research is a specialty analgesic CRO, research site, and
regulatory consulting firm supporting all phases of discovery for
analgesic treatments and has played a role in 10 analgesic FDA
approvals. Led by Dr. Neil Singla,
Lotus focuses on optimizing design/conduct of clinical trials in
pain providing scientific leadership at every step of the
development process. In assisting with the advancement of pain
therapies, Lotus Clinical Research seeks to invent and
operationalize research methods that improve study design and
conduct for analgesic trials, which support our mission to help
alleviate the U.S. opioid crisis and enhance the safe treatment of
pain worldwide.
Contact:
Hadley Rakowski
Lotus Clinical Research
802-343-5470
hrakowski@lotuscr.com
www.lotuscr.com
Related Images
lotus-logo.png
Lotus Logo
Related Links
Lotus Website
Lotus LinkedIn
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accelerating-development-of-non-opioid-pain-medicines-300855230.html
SOURCE Lotus Clinical Research